181 related articles for article (PubMed ID: 15168218)
1. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Gluck MR; Santana LA; Granson H; Yahr MD
J Neural Transm (Vienna); 2004 Jun; 111(6):713-24. PubMed ID: 15168218
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
3. [Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Mannisto PT
Biull Eksp Biol Med; 1998 Feb; 125(2):168-71. PubMed ID: 9559129
[No Abstract] [Full Text] [Related]
4. Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum.
Nowak P; Bortel A; Dabrowska J; Biedka I; Slomian G; Roczniak W; Kostrzewa RM; Brus R
Neurotox Res; 2008; 13(3-4):231-40. PubMed ID: 18522902
[TBL] [Abstract][Full Text] [Related]
5. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
6. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
8. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
9. Intracerebral dialysis monitoring of striatal dopamine release and metabolism in response to L-dopa.
Brannan T; Knott P; Kaufmann H; Leung L; Yahr M
J Neural Transm; 1989; 75(2):149-57. PubMed ID: 2918307
[TBL] [Abstract][Full Text] [Related]
10. Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Lin L; Meng T; Liu T; Zheng Z
Life Sci; 2013 Mar; 92(4-5):311-6. PubMed ID: 23333823
[TBL] [Abstract][Full Text] [Related]
11. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
Meissner W; Ravenscroft P; Reese R; Harnack D; Morgenstern R; Kupsch A; Klitgaard H; Bioulac B; Gross CE; Bezard E; Boraud T
Neurobiol Dis; 2006 Jun; 22(3):586-98. PubMed ID: 16531050
[TBL] [Abstract][Full Text] [Related]
12. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Dethy S; Laute MA; Damhaut P; Goldman S
J Neural Transm (Vienna); 1999; 106(2):145-58. PubMed ID: 10226935
[TBL] [Abstract][Full Text] [Related]
13. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
Brannan T; Knott P; Kaufmann H; Yahr M
Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
[No Abstract] [Full Text] [Related]
14. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
[TBL] [Abstract][Full Text] [Related]
15. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
16. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine.
Moroz IA; Peciña S; Schallert T; Stewart J
Exp Neurol; 2004 Sep; 189(1):78-93. PubMed ID: 15296838
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
18. Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Tanaka K; Ogawa N
Neurosci Res; 2005 Jan; 51(1):9-13. PubMed ID: 15596235
[TBL] [Abstract][Full Text] [Related]
19. The effect of a subchronic post-lesion treatment with (-)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and d-amphetamine.
Spooren WP; Waldmeier P; Gentsch C
J Neural Transm (Vienna); 1999; 106(9-10):825-33. PubMed ID: 10599865
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
